Pioglitazone-Enhanced Brown Fat Whitening Contributes to Weight Gain in Diet-Induced Obese Mice

 

 Buy Article Permissions and Reprints

Abstract

Introduction Pioglitazone is an insulin sensitizer used for the treatment of type 2 diabetes mellitus (T2DM) by activating peroxisome proliferator-activated receptor gamma. This study aimed to investigate the effects of pioglitazone on white adipose tissue (WAT) and brown adipose tissue (BAT) in diet-induced obese (DIO) mice.

Methods C57BL/6 mice were treated with pioglitazone (30 mg/kg/day) for 4 weeks after a 16-week high-fat diet (HFD) challenge. Body weight gain, body fat mass, energy intake, and glucose homeostasis were measured during or after the treatment. Histopathology was observed by hematoxylin and eosin, oil red O, immunohistochemistry, and immunofluorescence staining. Expression of thermogenic and mitochondrial biogenesis-related genes was detected by quantitative real-time PCR and western blotting.

Results After 4-week pioglitazone treatment, the fasting blood glucose levels, glucose tolerance, and insulin sensitivity were significantly improved, but the body weight gain and fat mass were increased in DIO mice. Compared with the HFD group, pioglitazone did not significantly affect the weights of liver and WAT in both subcutaneous and epididymal regions. Unexpectedly, the weight of BAT was increased after pioglitazone treatment. Histological staining revealed that pioglitazone ameliorated hepatic steatosis, reduced the adipocyte size in WAT, but increased the adipocyte size in BAT.

Conclusion Though pioglitazone can promote lipolysis, thermogenesis, and mitochondrial function in WAT, it leads to impaired thermogenesis, and mitochondrial dysfunction in BAT. In conclusion, pioglitazone could promote the browning of WAT but led to the whitening of BAT; the latter might be a new potential mechanism of pioglitazone-induced weight gain during T2DM treatment.

Publication History

Received: 13 June 2023
Received: 19 September 2023

Accepted: 10 August 2023
Accepted: 20 September 2023

Accepted Manuscript online:
20 September 2023

Article published online:
03 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Sun H, Saeedi P, Karuranga S. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119 DOI: 10.1016/j.diabres.2021.109119.
  CrossrefPubMedGoogle Scholar
• 2 Ahmad E, Lim S, Lamptey R. et al. Type 2 diabetes. Lancet 2022; 400: 1803-1820 DOI: 10.1016/s0140-6736(22)01655-5.
  CrossrefPubMedGoogle Scholar
• 3 Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019; 576: 51-60 DOI: 10.1038/s41586-019-1797-8.
  CrossrefPubMedGoogle Scholar
• 4 Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016; 37: 278-316 DOI: 10.1210/er.2015-1137.
  CrossrefPubMedGoogle Scholar
• 5 Tanase DM, Gosav EM, Costea CF. et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res 2020; 2020: 3920196 DOI: 10.1155/2020/3920196.
  CrossrefPubMedGoogle Scholar
• 6 Filipova E, Uzunova K, Kalinov K. et al. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr 2017; 9: 90 DOI: 10.1186/s13098-017-0290-5.
  CrossrefPubMedGoogle Scholar
• 7 Stump M, Mukohda M, Hu C. et al. PPARγ Regulation in hypertension and metabolic syndrome. Curr Hypertens Rep 2015; 17: 89 DOI: 10.1007/s11906-015-0601-x.
  CrossrefPubMedGoogle Scholar
• 8 Lingvay I, Sumithran P, Cohen RV. et al. Obesity management as a primary treatment goal for type 2 diabetes: Time to reframe the conversation. Lancet 2022; 399: 394-405 DOI: 10.1016/s0140-6736(21)01919-x.
  CrossrefPubMedGoogle Scholar
• 9 Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov 2016; 15: 639-660 DOI: 10.1038/nrd.2016.75.
  CrossrefPubMedGoogle Scholar
• 10 Scheja L, Heeren J. Metabolic interplay between white, beige, brown adipocytes and the liver. J Hepatol 2016; 64: 1176-1186 DOI: 10.1016/j.jhep.2016.01.025.
  CrossrefPubMedGoogle Scholar
• 11 Cohen P, Kajimura S. The cellular and functional complexity of thermogenic fat. Nat Rev Mol Cell Biol 2021; DOI: 10.1038/s41580-021-00350-0.. doi:10.1038/s41580-021-00350-0
  CrossrefPubMedGoogle Scholar
• 12 Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol 2014; 10: 24-36 DOI: 10.1038/nrendo.2013.204.
  CrossrefPubMedGoogle Scholar
• 13 Bartelt A, Bruns OT, Reimer R. et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011; 17: 200-205 DOI: 10.1038/nm.2297.
  CrossrefPubMedGoogle Scholar
• 14 Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med 2020; 7: 22 DOI: 10.3389/fcvm.2020.00022.
  CrossrefPubMedGoogle Scholar
• 15 Mottillo EP, Desjardins EM, Crane JD. et al. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue Function. Cell Metab 2016; 24: 118-129 DOI: 10.1016/j.cmet.2016.06.006.
  CrossrefPubMedGoogle Scholar
• 16 Takada I, Makishima M. Peroxisome proliferator-activated receptor agonists and antagonists: A patent review (2014-present). Expert Opin Ther Pat 2020; 30: 1-13 DOI: 10.1080/13543776.2020.1703952.
  CrossrefPubMedGoogle Scholar
• 17 Musso G, Cassader M, Paschetta E. et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med 2017; 177: 633-640 DOI: 10.1001/jamainternmed.2016.9607.
  CrossrefPubMedGoogle Scholar
• 18 Legchenko E, Chouvarine P, Borchert P. et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med 2018; 10 DOI: 10.1126/scitranslmed.aao0303.
  CrossrefPubMedGoogle Scholar
• 19 Ipsen E, Madsen KS, Chi Y. et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2020; 11: Cd013516 DOI: 10.1002/14651858.CD013516.pub2.
  CrossrefPubMedGoogle Scholar
• 20 Cusi K, Orsak B, Bril F. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med 2016; 165: 305-315 DOI: 10.7326/m15-1774.
  CrossrefPubMedGoogle Scholar
• 21 Kim JM, Kim SS, Kim JH. et al. Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: A randomized, open-label, multicenter, parallel-controlled study. Diabetes Metab J 2020; 44: 67-77 DOI: 10.4093/dmj.2018.0274.
  CrossrefPubMedGoogle Scholar
• 22 Han CL, Qu CZ. Cardiovascular risk and safety evaluation of a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, aleglitazar, in patients with type 2 diabetes: A meta-analysis. J Cardiovasc Pharmacol 2020; 75: 351-357 DOI: 10.1097/fjc.0000000000000796.
  CrossrefPubMedGoogle Scholar
• 23 Gross B, Pawlak M, Lefebvre P. et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 2017; 13: 36-49 DOI: 10.1038/nrendo.2016.135.
  CrossrefPubMedGoogle Scholar
• 24 Tontonoz P, Spiegelman BM. Fat and beyond: The diverse biology of PPARγ. Ann Rev Biochem 2008; 77: 289-312 DOI: 10.1146/annurev.biochem.77.061307.091829.
  CrossrefPubMedGoogle Scholar
• 25 Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26: 244-251 DOI: 10.1016/j.tips.2005.03.003.
  CrossrefPubMedGoogle Scholar
• 26 Zheng X, Xu F, Liang H. et al. SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress. Hepatology (Baltimore, Md) 2017; 66: 809-824 DOI: 10.1002/hep.29238.
  CrossrefPubMedGoogle Scholar
• 27 Cao H, Cai Q, Guo W. et al. Malonylation of acetyl-CoA carboxylase 1 promotes hepatic steatosis and is attenuated by ketogenic diet in NAFLD. Cell Rep 2023; 42: 112319 DOI: 10.1016/j.celrep.2023.112319.
  CrossrefPubMedGoogle Scholar
• 28 Xu F, Lin B, Zheng X. et al. GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia 2016; 59: 1059-1069 DOI: 10.1007/s00125-016-3896-5.
  CrossrefPubMedGoogle Scholar
• 29 Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999; 42: 1033-1049 DOI: 10.1007/s001250051268.
  CrossrefPubMedGoogle Scholar
• 30 Janani C, Ranjitha Kumari BD. PPAR gamma gene – A review. Diabetes Metab Syndr 2015; 9: 46-50 DOI: 10.1016/j.dsx.2014.09.015.
  CrossrefPubMedGoogle Scholar
• 31 Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: Unravelling the mechanism. The Lancet 2010; 375: 2267-2277 DOI: 10.1016/S0140-6736(10)60408-4.
  CrossrefPubMedGoogle Scholar
• 32 Cedikova M, Kripnerová M, Dvorakova J. et al. Mitochondria in white, brown, and beige adipocytes. Stem Cells Int 2016; 2016: 6067349 DOI: 10.1155/2016/6067349.
  CrossrefPubMedGoogle Scholar
• 33 Heinonen S, Jokinen R, Rissanen A. et al. White adipose tissue mitochondrial metabolism in health and in obesity. Obes Rev 2020; 21: e12958 DOI: 10.1111/obr.12958.
  CrossrefPubMedGoogle Scholar
• 34 Boengler K, Kosiol M, Mayr M. et al. Mitochondria and ageing: Role in heart, skeletal muscle and adipose tissue. J Cachexia Sarcopenia Muscle 2017; 8: 349-369 DOI: 10.1002/jcsm.12178.
  CrossrefPubMedGoogle Scholar
• 35 Altshuler-Keylin S, Kajimura S. Mitochondrial homeostasis in adipose tissue remodeling. Sci Signal 2017; 10 DOI: 10.1126/scisignal.aai9248.
  CrossrefPubMedGoogle Scholar
• 36 Wang W, Zhang Y, Wang Z. et al. A native drug-free macromolecular therapeutic to trigger mutual reinforcing of endoplasmic reticulum stress and mitochondrial dysfunction for cancer treatment. ACS Nano 2023; 17: 11023-11038 DOI: 10.1021/acsnano.3c03450.
  CrossrefPubMedGoogle Scholar
• 37 Wang J, Wang K, Ding L. et al. Alleviating effect of quercetin on cadmium-induced oxidative damage and apoptosis by activating the Nrf2-keap1 pathway in BRL-3A cells. Front Pharmacol 2022; 13: 969892 DOI: 10.3389/fphar.2022.969892.
  CrossrefPubMedGoogle Scholar
• 38 Harms MJ, Ishibashi J, Wang W. et al. Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice. Cell Metab 2014; 19: 593-604 DOI: 10.1016/j.cmet.2014.03.007.
  CrossrefPubMedGoogle Scholar
• 39 Boström P, Wu J, Jedrychowski MP. et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468 DOI: 10.1038/nature10777.
  CrossrefPubMedGoogle Scholar
• 40 Montanari T, Pošćić N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev 2017; 18: 495-513 DOI: 10.1111/obr.12520.
  CrossrefPubMedGoogle Scholar
• 41 Loh RKC, Formosa MF, Eikelis N. et al. Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: A randomised, controlled trial in humans. Diabetologia 2018; 61: 220-230 DOI: 10.1007/s00125-017-4479-9.
  CrossrefPubMedGoogle Scholar

• Supplementary Material